Effect of beta-Blocker Bisoprolol on Function of Hibernating Myocardium in Patients with Chronic Heart Failure of Ischemic Etiology
Ivanenko, V.V.; Riazantseva, N.V.; Tarasov, D.L.; Lopatin, I.M.
Kardiologiia 44(7): 57-61
2004
ISSN/ISBN: 0022-9040 PMID: 15340348 Document Number: 573366
To elucidate effect of beta-blocker bisoprolol on hibernating myocardium in patients with congestive heart failure (CHF) of ischaemic etiology without concomitant use of angiotensin converting enzyme inhibitors. Men (n=21, mean age 51,1+/-2,3 years) with NYHA class II-III congestive heart failure were divided into 2 groups according to results of dobutamine stress-echocardiography: with (group I, n=11), and without (group II, n=10) hibernating myocardium. All patients received bisoprolol (mean daily dose 8.9+/-0.5 mg) for 6 months. In both groups treatment was associated with NYHA class lowering (36.7%, p=0.002, in group 1, and 33.5%, p=0.02, in group II), significant increase of tolerance to physical exercise, improvement of quality of life. Left ventricular ejection fraction significantly increased (+10.5%, p=0.008) in patients with hibernating myocardium and practically did not change in group II (+4,8%, p=0,08). Meanwhile number of normokinetic zones increased by 94,4% in group I (p=0.008) and by 37,5% (p=0,02) in group II. This was associated with reduction of wall motion score index by 10.6%, p=0,009, and 8.2%, p=0,009, respectively. These results evidence for efficacy of treatment of patients with heart failure and hibernating myocardium with beta-blocker bisoprolol. In patients with heart failure of ischemic etiology bisoprolol facilitates transition of a part of myocardium from hypokinetic to normokinetic state.